Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD

Immunology Letters

Volumn 128, Issue 2, 2010, Pages 131-136

  Kuo, Yung Bin ^a   Chang, C Allen ^a   Wu, Yao Kuang ^b   Hsieh, Meng Jer ^c   Tsai, Chung Hsien ^d   Chen, Kuei Tien ^d   Chen, Chun Yu ^d   Chan, Err Cheng ^d  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Autoimmunity; COPD; Cytokeratin

Indexed keywords

AUTOANTIGEN; CELL ANTIGEN; CELL PROTEIN; CYTOKERATIN 18; CYTOKERATIN 18 ANTIBODY; CYTOKERATIN ANTIBODY; UNCLASSIFIED DRUG;

AGED; AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; CELLS, CULTURED; FORCED EXPIRATORY VOLUME; HUMANS; KERATIN-18; MALE; MIDDLE AGED; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77249147403     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.12.017     Document Type: Article

References (46)

1. Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412.
2. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
3. Ramsey S.D., Hobbs F.D. Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. Proc Am Thorac Soc 2006, 3:635-640.
4. Hodge S., Hodge G., Holmes M., Reynolds P.N. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005, 25:447-454.
5. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
6. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
7. Agusti A., Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006, 3:478-481.
8. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
9. Agusti A., MacNee W., Donaldson K., Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 2003, 58:832-834.
10. Cosio M.G., Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 1999, 160:S21-S25.
11. Richmond I., Pritchard G.E., Ashcroft T., Avery A., Corris P.A., Walters E.H. Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers. Thorax 1993, 48:1130-1134.
12. Bosken C.H., Hards J., Gatter K., Hogg J.C. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis 1992, 145:911-917.
13. Casolaro M.A., Bernaudin J.F., Saltini C., Ferrans V.J., Crystal R.G. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988, 137:406-411.
14. Plumb J., Smyth L.J., Adams H.R., Vestbo J., Bentley A., Singh S.D. Increased T-regulatory cells within lymphocyte follicles in moderate COPD. Eur Respir J 2009, 34:89-94.
15. Sullivan A.K., Simonian P.L., Falta M.T., Mitchell J.D., Cosgrove G.P., Brown K.K., et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005, 172:590-596.
16. Taraseviciene-Stewart L., Scerbavicius R., Choe K.H., Moore M., Sullivan A., Nicolls M.R., et al. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005, 171:734-742.
17. Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:2445-2454.
18. Lee S.H., Goswami S., Grudo A., Song L.Z., Bandi V., Goodnight-White S., et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007, 13:567-569.
19. Feghali-Bostwick C.A., Gadgil A.S., Otterbein L.E., Pilewski J.M., Stoner M.W., Csizmadia E., et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:156-163.
20. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345:340-350.
21. Standardization of Spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
22. Muller N.L., Coxson H. Chronic obstructive pulmonary disease. 4. Imaging the lungs in patients with chronic obstructive pulmonary disease. Thorax 2002, 57:982-985.
23. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139-145.
24. Wu C.C., Chen H.C., Chen S.J., Liu H.P., Hsieh Y.Y., Yu C.J., et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8:316-332.
25. Taraseviciene-Stewart L., Douglas I.S., Nana-Sinkam P.S., Lee J.D., Tuder R.M., Nicolls M.R., et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease? Proc Am Thorac Soc 2006, 3:687-690.
26. Tzortzaki E.G., Siafakas N.M. A hypothesis for the initiation of COPD. Eur Respir J 2009, 34:310-315.
27. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002, 2:372-377.
28. Hodge S., Hodge G., Scicchitano R., Reynolds P.N., Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003, 81:289-296.
29. Rutgers S.R., Postma D.S., ten Hacken N.H., Kauffman H.F., van Der Mark T.W., Koeter G.H., et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Chest 2000, 117:262S.
30. Patel V.A., Longacre A., Hsiao K., Fan H., Meng F., Mitchell J.E., et al. Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells: implications for the delayed clearance model of autoimmunity. J Biol Chem 2006, 281:4663-4670.
31. Krysko D.V., D'Herde K., Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006, 11:1709-1726.
32. Moll R., Franke W.W., Schiller D.L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31:11-24.
33. Steinert P.M. Structure, function, and dynamics of keratin intermediate filaments. J Invest Dermatol 1993, 100:729-734.
34. Blobel G.A., Moll R., Franke W.W., Vogt-Moykopf I. Cytokeratins in normal lung and lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. Virchows Arch B Cell Pathol Incl Mol Pathol 1984, 45:407-429.
35. Leers M.P., Kolgen W., Bjorklund V., Bergman T., Tribbick G., Persson B., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999, 187:567-572.
36. Caulin C., Salvesen G.S., Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997, 138:1379-1394.
37. Nahm D.H., Lee Y.E., Yim E.J., Park H.S., Yim H., Kang Y., et al. Identification of cytokeratin 18 as a bronchial epithelial autoantigen associated with nonallergic asthma. Am J Respir Crit Care Med 2002, 165:1536-1539.
38. Murota M., Nishioka M., Fujita J., Dobashi N., Wu F., Ohtsuki Y., et al. Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis. Clin Exp Immunol 2001, 125:291-299.
39. Dobashi N., Fujita J., Murota M., Ohtsuki Y., Yamadori I., Yoshinouchi T., et al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000, 178:171-179.
40. Leidinger P., Keller A., Heisel S., Ludwig N., Rheinheimer S., Klein V., et al. Novel autoantigens immunogenic in COPD patients. Respir Res 2009, 10:20.
41. ter Borg E.J., Horst G., Hummel E.J., Limburg P.C., Kallenberg C.G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990, 33:634-643.
42. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
43. Linder S. Cytokeratin markers come of age. Tumour Biol 2007, 28:189-195.
44. Barak V., Goike H., Panaretakis K.W., Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004, 37:529-540.
45. Nisman B., Lafair J., Heching N., Lyass O., Baras M., Peretz T., et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998, 82:1850-1859.
46. Linder S., Havelka A.M., Ueno T., Shoshan M.C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004, 214:1-9.